| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock | Sale | -$261K | -13.1K | -5.96% | $20.00 | 206K | Aug 3, 2023 | Direct | F1, F2 |
| transaction | PLRX | Common Stock | Options Exercise | $3.74K | +1.8K | +0.87% | $2.08* | 208K | Aug 3, 2023 | Direct | |
| transaction | PLRX | Common Stock | Sale | $36K | +1.8K | +0.88% | $20.00 | 206K | Aug 3, 2023 | Direct | F1, F3 |
| transaction | PLRX | Common Stock | Options Exercise | $18.3K | +8.79K | +4.27% | $2.08* | 215K | Aug 4, 2023 | Direct | |
| transaction | PLRX | Common Stock | Sale | -$401K | -20.1K | -9.33% | $20.01 | 195K | Aug 4, 2023 | Direct | F1, F3 |
| holding | PLRX | Common Stock | 3.82K | Aug 3, 2023 | See footnote | F4 | |||||
| holding | PLRX | Common Stock | 14K | Aug 3, 2023 | See footnote | F5 | |||||
| holding | PLRX | Common Stock | 14K | Aug 3, 2023 | See footnote | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock (Right to Buy) | Options Exercise | $0 | -1.8K | -4.29% | $0.00 | 40.2K | Aug 3, 2023 | Common Stock | 1.8K | $2.08 | Direct | F7 |
| transaction | PLRX | Common Stock (Right to Buy) | Options Exercise | $0 | -8.79K | -21.89% | $0.00 | 31.4K | Aug 4, 2023 | Common Stock | 8.79K | $2.08 | Direct | F7 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. |
| F4 | The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose. |
| F5 | The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| F6 | The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| F7 | On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer. |